Optimi Health Corp. (TSE:OPTI) has released an update.
Optimi Health Corp., a leader in psychedelics pharmaceuticals, has achieved a milestone by receiving a Certificate of Analysis for its GMP-compliant natural psilocybin extract and successfully completing in-house encapsulation in 5mg and 10mg dosages. These developments indicate a significant step towards the product’s market readiness, backed by positive validation on potency and stability, and signal Optimi’s readiness to meet emerging market demands with its in-house production capabilities.
For further insights into TSE:OPTI stock, check out TipRanks’ Stock Analysis page.
